Supernus Pharmaceuticals, Inc. (0LB2.L)
USD 31.44
(-2.48%)
USD 31.44
(-2.48%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 33.19 Million USD | -7.78% |
| 2022 | 35.99 Million USD | -91.44% |
| 2021 | 420.55 Million USD | 7.74% |
| 2020 | 390.33 Million USD | 3.92% |
| 2019 | 375.61 Million USD | 14.01% |
| 2018 | 329.46 Million USD | 1380.2% |
| 2017 | 22.25 Million USD | 434.41% |
| 2016 | 4.16 Million USD | -42.06% |
| 2015 | 7.18 Million USD | -73.32% |
| 2014 | 26.94 Million USD | -21.65% |
| 2013 | 34.39 Million USD | 210.18% |
| 2012 | 11.08 Million USD | -51.18% |
| 2011 | 22.71 Million USD | -69.72% |
| 2010 | 75 Million USD | 0.0% |
| 2009 | 75 Million USD | 0.0% |
| 2008 | 75 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 30.29 Million USD | 0.0% |
| 2024 Q3 | 28.92 Million USD | 0.0% |
| 2024 Q1 | 32.99 Million USD | 0.0% |
| 2023 Q2 | 34.17 Million USD | -6.39% |
| 2023 Q1 | 36.51 Million USD | 1.43% |
| 2023 Q4 | 33.19 Million USD | -1.91% |
| 2023 FY | 33.19 Million USD | -7.78% |
| 2023 Q3 | 33.84 Million USD | -0.98% |
| 2022 Q4 | 35.99 Million USD | -0.08% |
| 2022 FY | 35.99 Million USD | -91.44% |
| 2022 Q1 | 440.27 Million USD | 4.69% |
| 2022 Q2 | 37.08 Million USD | -91.58% |
| 2022 Q3 | 36.02 Million USD | -2.84% |
| 2021 Q2 | 406.52 Million USD | 3.03% |
| 2021 Q4 | 420.55 Million USD | 2.06% |
| 2021 Q1 | 394.57 Million USD | 1.09% |
| 2021 FY | 420.55 Million USD | 7.74% |
| 2021 Q3 | 412.04 Million USD | 1.36% |
| 2020 Q3 | 406.33 Million USD | 1.12% |
| 2020 Q1 | 380.03 Million USD | 1.18% |
| 2020 Q2 | 401.83 Million USD | 5.74% |
| 2020 FY | 390.33 Million USD | 3.92% |
| 2020 Q4 | 390.33 Million USD | -3.94% |
| 2019 Q4 | 375.61 Million USD | 1.95% |
| 2019 FY | 375.61 Million USD | 14.01% |
| 2019 Q1 | 361.13 Million USD | 9.61% |
| 2019 Q2 | 364.74 Million USD | 1.0% |
| 2019 Q3 | 368.41 Million USD | 1.01% |
| 2018 Q1 | 318.22 Million USD | 1329.71% |
| 2018 Q4 | 329.46 Million USD | 1.17% |
| 2018 FY | 329.46 Million USD | 1380.2% |
| 2018 Q3 | 325.66 Million USD | 1.16% |
| 2018 Q2 | 321.92 Million USD | 1.16% |
| 2017 Q3 | 22.7 Million USD | 1442.26% |
| 2017 FY | 22.25 Million USD | 434.41% |
| 2017 Q1 | 3.31 Million USD | -20.53% |
| 2017 Q2 | 1.47 Million USD | -55.53% |
| 2017 Q4 | 22.25 Million USD | -1.96% |
| 2016 FY | 4.16 Million USD | -42.06% |
| 2016 Q4 | 4.16 Million USD | -27.84% |
| 2016 Q3 | 5.77 Million USD | 1.28% |
| 2016 Q2 | 5.69 Million USD | 1.28% |
| 2016 Q1 | 5.62 Million USD | -21.73% |
| 2015 Q4 | 7.18 Million USD | -10.89% |
| 2015 FY | 7.18 Million USD | -73.32% |
| 2015 Q1 | 11.7 Million USD | -56.55% |
| 2015 Q2 | 8.76 Million USD | -25.16% |
| 2015 Q3 | 8.06 Million USD | -7.92% |
| 2014 Q1 | 28.35 Million USD | -17.55% |
| 2014 FY | 26.94 Million USD | -21.65% |
| 2014 Q4 | 26.94 Million USD | 1.7% |
| 2014 Q3 | 26.49 Million USD | -7.58% |
| 2014 Q2 | 28.67 Million USD | 1.1% |
| 2013 Q4 | 34.39 Million USD | -42.85% |
| 2013 FY | 34.39 Million USD | 210.18% |
| 2013 Q1 | 7.97 Million USD | -28.08% |
| 2013 Q2 | 59.1 Million USD | 641.07% |
| 2013 Q3 | 60.17 Million USD | 1.82% |
| 2012 Q1 | 19.92 Million USD | -12.26% |
| 2012 Q2 | 17.06 Million USD | -14.38% |
| 2012 FY | 11.08 Million USD | -51.18% |
| 2012 Q4 | 11.08 Million USD | -21.45% |
| 2012 Q3 | 14.11 Million USD | -17.26% |
| 2011 Q3 | 86 Million USD | 0.0% |
| 2011 Q4 | 22.71 Million USD | -73.59% |
| 2011 FY | 22.71 Million USD | -69.72% |
| 2010 FY | 75 Million USD | 0.0% |
| 2010 Q3 | 75 Million USD | 0.0% |
| 2010 Q4 | 75 Million USD | 0.0% |
| 2009 FY | 75 Million USD | 0.0% |
| 2009 Q4 | 75 Million USD | 0.0% |
| 2008 FY | 75 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | 74.477% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 41.749% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 91.441% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 27.35% |
| bluebird bio, Inc. | 224.41 Million USD | 85.208% |
| Cara Therapeutics, Inc. | 37.07 Million USD | 10.472% |
| Imunon, Inc. | 1.13 Million USD | -2813.737% |
| Editas Medicine, Inc. | 24.37 Million USD | -36.205% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 99.744% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 98.32% |
| Myriad Genetics, Inc. | 130.9 Million USD | 74.64% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 87.148% |
| Verastem, Inc. | 40.08 Million USD | 17.188% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 99.587% |
| Waters Corporation | 2.3 Billion USD | 98.56% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.894% |
| Biogen Inc. | 7.18 Billion USD | 99.538% |
| Nektar Therapeutics | 112.62 Million USD | 70.525% |
| Perrigo Company plc | 3.63 Billion USD | 99.086% |
| Dynavax Technologies Corporation | 252.41 Million USD | 86.849% |
| Illumina, Inc. | 1.48 Billion USD | 97.771% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -925.001% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -3219.6% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 80.895% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -41.026% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 94.403% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | 0.952% |
| Evolus, Inc. | 120.35 Million USD | 72.419% |
| Adicet Bio, Inc. | 17.7 Million USD | -87.516% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -979.896% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 98.772% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 93.381% |
| FibroGen, Inc. | 89.69 Million USD | 62.991% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 98.786% |
| OPKO Health, Inc. | 222.03 Million USD | 85.049% |
| Homology Medicines, Inc. | 43.17 Million USD | 23.115% |
| Geron Corporation | 35.05 Million USD | 5.292% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 98.583% |
| Exelixis, Inc. | 189.94 Million USD | 82.523% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -3446.581% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 65.688% |
| Zoetis Inc. | 6.56 Billion USD | 99.494% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 81.358% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -654.112% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 95.419% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 2.907% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 97.629% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 97.069% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 97.786% |
| Blueprint Medicines Corporation | 610.96 Million USD | 94.567% |
| Insmed Incorporated | 1.19 Billion USD | 97.218% |
| TG Therapeutics, Inc. | 100.11 Million USD | 66.843% |
| Incyte Corporation | 29.16 Million USD | -13.833% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 92.565% |